5371W-13 A DOUBLE-BLIND PLACEBO-CONTROLLED SINGLE ASCENDING INTRAVENOUS INFUSION STUDY OF RHIGM22 IN

A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of rHIgM22 in Patients with Multiple Sclerosis.

Type of Study
Neuroscience - Multiple Sclerosis
Short Description

To evaluate the safety and tolerability of single ascending doses of rHIgM22 in patients with Multiple Sclerosis.

Status
Open
Principal Investigator
James Bowen, MD
Eligibility Notes

Adult men and women between 18 and 70 years of age with no MS relapses within 30 days prior to screening and no treatment with corticosteroids, except for topical preparations, within 30 days prior to screening.

Contact Name
Yuriko Courtney and Beena Gangadharan
Phone
206-320-2647
Alternate Phone
206-320-2633
Email
yuriko.courtney@swedish.org
Alternate Email
beena.gangadharan@swedish.org